Zevin Asset Management LLC Trims Stake in Pfizer Inc. (NYSE:PFE)

Zevin Asset Management LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 4.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,810 shares of the biopharmaceutical company’s stock after selling 400 shares during the quarter. Zevin Asset Management LLC’s holdings in Pfizer were worth $317,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of PFE. Nuveen Asset Management LLC raised its position in Pfizer by 2,240.5% in the 2nd quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock worth $1,563,256,000 after purchasing an additional 34,544,423 shares during the period. Natixis purchased a new stake in Pfizer in the 2nd quarter worth about $258,466,000. Invesco Ltd. raised its position in Pfizer by 14.6% in the 2nd quarter. Invesco Ltd. now owns 21,118,606 shares of the biopharmaceutical company’s stock worth $914,857,000 after purchasing an additional 2,693,349 shares during the period. DNB Asset Management AS raised its position in Pfizer by 241.0% in the 3rd quarter. DNB Asset Management AS now owns 3,734,044 shares of the biopharmaceutical company’s stock worth $134,164,000 after purchasing an additional 2,638,873 shares during the period. Finally, Thoroughbred Financial Services LLC raised its position in Pfizer by 4,297.8% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 2,656,678 shares of the biopharmaceutical company’s stock worth $265,668,000 after purchasing an additional 2,596,269 shares during the period. 71.52% of the stock is currently owned by institutional investors.

PFE has been the topic of a number of recent analyst reports. Credit Suisse Group reissued a “hold” rating and issued a $41.30 price objective on shares of Pfizer in a research report on Wednesday. ValuEngine upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. JPMorgan Chase & Co. restated a “neutral” rating on shares of Pfizer in a research note on Tuesday, October 29th. Morgan Stanley dropped their target price on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 27th. Finally, Bank of America began coverage on shares of Pfizer in a research note on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 target price on the stock. Nine equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $44.02.

In related news, Director Scott Gottlieb purchased 3,000 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was acquired at an average price of $34.72 per share, with a total value of $104,160.00. Following the completion of the acquisition, the director now owns 3,000 shares in the company, valued at approximately $104,160. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Pfizer Inc purchased 50,000 shares of the firm’s stock in a transaction on Tuesday, September 17th. The stock was bought at an average cost of $18.00 per share, with a total value of $900,000.00. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.

NYSE:PFE traded up $0.14 during midday trading on Friday, reaching $37.05. 24,924,227 shares of the stock traded hands, compared to its average volume of 23,366,957. Pfizer Inc. has a 12-month low of $33.97 and a 12-month high of $46.47. The business has a 50-day moving average of $36.62 and a two-hundred day moving average of $39.26. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47. The stock has a market capitalization of $207.30 billion, a PE ratio of 12.35, a price-to-earnings-growth ratio of 2.11 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.13. The company had revenue of $12.68 billion during the quarter, compared to analysts’ expectations of $12.37 billion. Pfizer had a net margin of 30.57% and a return on equity of 28.61%. Pfizer’s revenue for the quarter was down 4.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.78 earnings per share. Research analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a $0.36 dividend. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.89%. Pfizer’s dividend payout ratio is currently 48.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: Understanding debt-to-equity ratio in fundamental analysis

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.